2-ethoxy-4'-fluorobiphenyl-4-carbaldehyde | 909855-08-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-ethoxy-4'-fluorobiphenyl-4-carbaldehyde
• 英文别名: ethoxy-4'-fluoro-biphenyl-4-carbaldehyde；2-Ethoxy-4'-fluoro-biphenyl-4-carbaldehyde；3-ethoxy-4-(4-fluorophenyl)benzaldehyde
• CAS: 909855-08-9
• 化学式: C₁₅H₁₃FO₂
• 分子量: 244.265
• InChiKey: VBHZKUHPFRJFOZ-UHFFFAOYSA-N

物化性质

• 沸点：
  346.3±32.0 °C(Predicted)
• 密度：
  1.157±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-methyl-N-(piperidin-4-yl)-nicotinamide 、 2-ethoxy-4'-fluorobiphenyl-4-carbaldehyde 在 titanium(IV) isopropylate 、 sodium cyanoborohydride 作用下， 以 异丙醇 为溶剂， 反应 14.0h， 生成 N-[1-(2-ethoxy-4'-fluoro-biphenyl-4-ylmethyl)-piperidin-4-yl]-5-methyl-nicotinamide
  参考文献：
  名称：

  Piperidinyl-nicotinamides as potent and selective somatostatin receptor subtype 5 antagonists

  摘要：

  Nicotinamides of benzyl-substituted 4-aminopiperidines and their seven-membered analogs of generic structure 2 and 20 have been discovered as potent and selective SST5 antagonists. The activity (K-i) ranges from 2.4 to 436 nM. Most compounds exhibit decent physicochemical properties and follow a clear SAR pattern. Interestingly enough, the receptor is strongly enantiodiscriminating and binds in the amino-azepaneseries only the (R)-enantiomer. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.06.026
• 作为产物：
  描述：

  3-(苄氧基)-4-溴苯甲酸甲酯 在 2-双环己基膦-2',6'-二甲氧基联苯 、 tris-(dibenzylideneacetone)dipalladium(0) 、 lithium aluminium tetrahydride 、 四丙基高钌酸铵 、 potassium tert-butylate 、 氢气 、 palladium(II) hydroxide 、 sodium carbonate 、 N-甲基吗啉氧化物 作用下， 以 四氢呋喃 、 甲醇 、 水 、 甲苯 、 乙腈 为溶剂， 反应 6.5h， 生成 2-ethoxy-4'-fluorobiphenyl-4-carbaldehyde
  参考文献：
  名称：

  [EN] SPIRO AZETIDINE ISOXAZOLE DERIVATIVES AND THEIR USE AS SSTR5 ANTAGONISTS
  [FR] DÉRIVÉS DE SPIRO AZÉTIDINE ISOXAZOLE ET LEUR UTILISATION EN TANT QU'ANTAGONISTES DE SSTR5

  摘要：

  提供一个具有SSTR5拮抗作用的化合物，该化合物由以下公式（1）或其盐表示：其中每个符号的定义与说明书中相同。

  公开号：

  WO2014142363A1

文献信息

• BENZOIMIDAZOLE, TETRAHYDRO-QUINOXALINE, BENZOTRIAZOLE, DIHYDRO-IMIDAZO[4,5-c] PYRIDINONE AND DIHYDRO-ISOINDOLONE DERIVATIVES
  申请人：Bleicher Konrad

  公开号：US20080249101A1

  公开（公告）日：2008-10-09

  This invention relates to compounds of the formula wherein A, R 1 to R 3 are as defined in the specification and G is benzoimidazole, quinoxaline, benzotriazole, dihydro-imidazo[4,5-c]pyridine and dihydro-isoindolone group as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

  这项发明涉及以下式的化合物 其中A，R1至R3如规范中所定义，G为苯并咪唑，喹喔啉，苯并三唑，二氢咪唑[4,5-c]吡啶和二氢异吲哚酮基团，如规范中所定义，并其药学上可接受的盐。该发明还涉及含有这种化合物的药物组合物，以及用于制备它们的方法和它们用于治疗和/或预防与调节SST受体亚型5相关的疾病。
• ARYLOXAZOLE, ARYLOXADIAZOLE AND BENZIMIDAZOLE DERIVATIVES
  申请人：Christ Andreas D.

  公开号：US20080306116A1

  公开（公告）日：2008-12-11

  This invention relates to compounds of the formula wherein X is O or NR 8 , Y is CR 7 or N, and R 1 to R 8 are as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

  这项发明涉及以下式的化合物 其中X为O或NR 8 ，Y为CR 7 或N，R 1 至R 8 如规范中所定义，并且其药学上可接受的盐。该发明还涉及含有这种化合物的药物组合物，以及用于制备它们的过程以及它们用于治疗和/或预防与调节SST受体亚型5相关的疾病的用途。
• Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives
  申请人：Binggeli Alfred

  公开号：US20060205718A1

  公开（公告）日：2006-09-14

  This invention is concerned with compounds of the formula wherein A, B 1 , B 2 , R 1 , R 2 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

  这项发明涉及以下式的化合物 其中A、B 1 、B 2 、R 1 、R 2 和G如描述和索赔中所定义，并其药学上可接受的盐。该发明还涉及含有这种化合物的药物组合物，以及用于制备它们的方法和它们用于治疗和/或预防与调节SST受体亚型5相关的疾病的用途。
• Amide derivatives as somatostatin receptor 5 antagonists
  申请人：Binggeli Alfred

  公开号：US20060276508A1

  公开（公告）日：2006-12-07

  This invention is concerned with compounds of the formula wherein R 1 to R 5 , R 5′ and A are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

  这项发明涉及以下式中的化合物，其中R1至R5、R5'和A如描述和索赔中所定义，并且其药学上可接受的盐。该发明还涉及含有这种化合物的药物组合物，以及用于治疗和/或预防与调节SST受体亚型5相关的疾病的方法。
• Substituted n-benzyl piperidines as somatostatin receptor modulators
  申请人：Hoffmann-La Roche Inc.

  公开号：US07799806B2

  公开（公告）日：2010-09-21

  This invention relates to compounds of the formula wherein A, R1 to R3 are as defined in the claims and G is benzoimidazole, quinoxaline, benzotriazole, dihydro-imidazo[4,5-c]pyridinone and dihydro-isoindolone group as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5 such as diabetes mellitus.

  本发明涉及以下式子的化合物，其中A，R1到R3的定义见权利要求书，G为苯并咪唑，喹喔啉，苯并三唑，二氢咪唑并[4,5-c]吡啶酮和二氢异吲哚酮基团，如规范中所定义，并且其药学上可接受的盐。本发明进一步涉及含有这种化合物的制药组合物，以及用于治疗和/或预防与SST受体亚型5调节相关的疾病，例如糖尿病的用途的制备方法。